Phase 1/2 Study to Determine the Safety, Pharmacokinetics, and Efficacy of Single Agent CC-122 and the Combinations of CC-122 and Ibrutinib and CC-122 and Obinutuzumab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Trial Profile

Phase 1/2 Study to Determine the Safety, Pharmacokinetics, and Efficacy of Single Agent CC-122 and the Combinations of CC-122 and Ibrutinib and CC-122 and Obinutuzumab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 02 Aug 2017

At a glance

  • Drugs Avadomide (Primary) ; Ibrutinib; Obinutuzumab; Rituximab
  • Indications Chronic lymphocytic leukaemia
  • Focus Adverse reactions
  • Acronyms ENHANCE
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 31 May 2017 Planned number of patients changed from 172 to 152.
    • 31 May 2017 Planned End Date changed from 24 Jan 2020 to 18 Jul 2024.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top